During a Case-Based Roundtable® event, Andrew H. Lipsky, MD, moderated a discussion on the efficacy and safety of newer BTK ...

Brukinsa won approval for another blood cancer last month. ArQule's lead product candidate is a BTK inhibitor, ARQ-531, designed for heavily pretreated patients with leukemias and lymphomas ...

Shandong New Time Pharmaceutical Co. Ltd. has disclosed compounds acting as Bruton tyrosine kinase (BTK) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.

The BTK inhibitors market has experienced significant dynamics driven by advancements in oncology and autoimmune disease treatments. One of the primary drivers of the BTK inhibitors market is the ...

Jaypirca belongs to a class of medications called Bruton’s tyrosine kinase (BTK) inhibitors, which block a protein critical ...

Another of Principia’s BTK inhibitors, rilzabrutinib ... is expected to begin by the end of the year as long as COVID-19 does not impact on trials and there is also an ongoing phase 2 ...

A focus group is reviewing a new product and none of them believe it works. When asked for a testimonial, many in the group say the product is excellent.

Roche has presented more data from a Phase II study of its Bruton’s tyrosine kinase (BTK) inhibitor after long-term data ...

Nurix Therapeutics has reported positive clinical data from its ongoing Phase Ia/Ib trial of NX-5948 for Waldenstrom's ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...